irinotecan has been researched along with piperidines in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (7.41) | 18.2507 |
| 2000's | 10 (37.04) | 29.6817 |
| 2010's | 13 (48.15) | 24.3611 |
| 2020's | 2 (7.41) | 2.80 |
| Authors | Studies |
|---|---|
| Kizaki, H; Oguro, M; Onishi, Y | 2 |
| Bishop, JF; Clarke, SJ; Dodds, HM; Findlay, M; Rivory, LP; Robert, J | 1 |
| Gonen, M; Jung, C; Motwani, M; Schwartz, GK; Shah, MA; She, Y; Sirotnak, FM | 1 |
| Commes, T; Motwani, M; Schwartz, GK; She, Y; Sirotnak, FM | 1 |
| Ducreux, M; Köhne, CH; Schwartz, GK; Vanhoefer, U | 1 |
| Fortier, LC; Gagné, JF; Girard, H; Guillemette, C; Villeneuve, L | 1 |
| Brenner, B; Cordon-Cardo, C; Drobnjak, M; Gonen, M; Kelsen, DP; Kortmansky, J; Lefkowitz, R; Motwani, M; O'Reilly, E; Saltz, L; Schwartz, GK; Shah, MA; Tong, W; Weyerbacher, A; Yi, S | 1 |
| Fujimoto, K; Hirao, Y; Matsushita, C; Miyake, M; Tanaka, M; Tanaka, N | 1 |
| Ciardiello, F; Eckhardt, SG; Gustafson, DL; Henthorn, TK; Lockerbie, O; Long, M; Merz, A; Morrow, M; Serkova, NJ; Troiani, T | 1 |
| Ambrosini, G; Qin, LX; Schwartz, GK; Seelman, SL | 1 |
| Azzariti, A; Berardi, F; Colabufo, NA; D'Incalci, M; Paradiso, A; Perrone, R; Porcelli, L; Quatrale, AE; Simone, GM; Xu, JM; Zucchetti, M | 1 |
| Burd, R; Daskalakis, C; Dicker, AP; Ryan, A; Wachsberger, P | 1 |
| Ashwell, S; Brassil, PJ; Dai, J; Garner, CE; Gönen, M; Goteti, K; Kern, SE; Moustakas, DT; Schwartz, GK; Utley, L; Zabludoff, S | 1 |
| Chyi Lee, F; Fekrazad, HM; Rabinowitz, I; Royce, M; Smith, HO; Verschraegen, CF | 1 |
| Belcastro, V; Bosotti, R; Brunetti-Pierri, N; di Bernardo, D; Ferriero, R; Iorio, F; Isacchi, A; Mithbaokar, P; Murino, L; Scacheri, E; Tagliaferri, R | 1 |
| Cane, LM; Carvajal, RD; Dials, HJ; Dickson, MA; Gonen, M; Lefkowitz, RA; Rathkopf, D; Schwartz, GK; Shah, MA; Tse, A; Wu, N | 1 |
| Chen, C; Damek, D; Fields, EC; Gaspar, LE; Kavanagh, BD; Lillehei, K; Liu, AK; Waziri, A | 1 |
| Agelaki, S; Androulakis, N; Bozionelou, V; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Kalykaki, A; Kotsakis, A; Saridaki, Z; Vamvakas, L; Vardakis, N | 1 |
| Ackerstaff, E; Chen, JH; Darpolor, MM; Kennealey, PT; Koutcher, JA; Le, HC; Rizwan, A; Sambol, EB; Schwartz, GK; Singer, S; Zakian, KL | 1 |
| Takane, H | 1 |
| Abrams, TA; Ancukiewicz, M; Blaszkowsky, L; Chan, JA; Duda, DG; Elliott, M; Enzinger, PC; Goldstein, M; Jain, RK; Kulke, MH; Meyerhardt, JA; Regan, E; Schrag, D; Wolpin, BM; Zhu, AX | 1 |
| Ambudkar, SV; Bhatnagar, J; Chen, JJ; Chen, WM; Chen, ZS; Lan, P; Ruan, ZX; Shu, C; Sodani, K; Wang, J; Xiao, ZJ; Ye, WC; Zhang, DM | 1 |
| Hall, DG; Lavasanifar, A; Morgan, TDR; Shire, Z; Vakili, MR; Weinfeld, M | 1 |
| Bascal, Z; Caine, M; Czuczman, P; Garcia, P; Hagan, A; Kilpatrick, H; Lewis, AL; Lloyd, AW; Macfarlane, WM; Phillips, G; Press, C; Tang, Y | 1 |
| Kaushik, AC; Wang, X; Wang, YJ; Wei, DQ | 1 |
| Belli, V; Cardone, C; Ciardiello, D; Ciardiello, F; De Falco, V; Della Corte, C; Desiderio, V; Giunta, EF; Martinelli, E; Martini, G; Matrone, N; Mele, L; Morgillo, F; Napolitano, S; Papaccio, G; Poliero, L; Selvaggi, F; Tirino, V; Troiani, T; Vitiello, PP | 1 |
2 review(s) available for irinotecan and piperidines
| Article | Year |
|---|---|
Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Cyclooxygenase 2; Deoxycytidine; Drug Administration Schedule; Enzyme Inhibitors; Flavonoids; Fluorouracil; Humans; Immunologic Factors; Irinotecan; Isoenzymes; Leucovorin; Membrane Proteins; Organoplatinum Compounds; Oxaliplatin; Piperidines; Prostaglandin-Endoperoxide Synthases; Quinazolines; Thiophenes; Treatment Outcome | 2003 |
[Genetic polymorphisms of SLCO1B1 for drug pharmacokinetics and its clinical implications].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antineoplastic Agents, Phytogenic; Camptothecin; Carbamates; Haplotypes; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Irinotecan; Liver; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters; Pharmacogenetics; Piperidines; Polymorphism, Genetic | 2011 |
5 trial(s) available for irinotecan and piperidines
| Article | Year |
|---|---|
A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Camptothecin; Cell Cycle Proteins; Cyclin-Dependent Kinase Inhibitor p21; Drug Administration Schedule; Drug Interactions; Female; Flavonoids; Humans; Intracellular Signaling Peptides and Proteins; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Piperidines; Treatment Outcome; Tumor Suppressor Protein p53 | 2005 |
A phase I study of flavopiridol in combination with gemcitabine and irinotecan in patients with metastatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Flavonoids; Gemcitabine; Humans; Irinotecan; Life Expectancy; Male; Middle Aged; Neoplasm Metastasis; Patient Selection; Piperidines | 2010 |
A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Flavonoids; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Piperidines; Protein Kinase Inhibitors; Treatment Outcome | 2010 |
Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carboplatin; Cohort Studies; Combined Modality Therapy; Dacarbazine; Dexamethasone; Drug Administration Schedule; Female; Glioma; Glucocorticoids; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Prospective Studies; Quinazolines; Radiosurgery; Radiotherapy Dosage; Temozolomide; Tumor Burden; Vincristine; Young Adult | 2012 |
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Piperidines; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome; Vascular Endothelial Growth Factors | 2012 |
20 other study(ies) available for irinotecan and piperidines
| Article | Year |
|---|---|
A lymphoma cell line resistant to 4-piperidinopiperidine was less sensitive to CPT-11.
Topics: Antineoplastic Agents; Camptothecin; Cell Division; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Etoposide; Humans; Irinotecan; Lymphoma, T-Cell; Piperidines; Tumor Cells, Cultured | 1997 |
4-Piperidinopiperidine-resistant lymphoma cells were resistant to dexamethasone- and A23187-induced apoptosis.
Topics: Apoptosis; Calcimycin; Camptothecin; Dexamethasone; DNA Fragmentation; Drug Resistance; Humans; Irinotecan; Lymphoma; Piperidines; Tumor Cells, Cultured | 1998 |
Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Half-Life; Humans; Irinotecan; Mass Spectrometry; Piperidines | 2000 |
Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Colonic Neoplasms; Flavonoids; Humans; Irinotecan; Male; Mice; Mice, Nude; Piperidines; Transplantation, Heterologous; Tumor Cells, Cultured | 2001 |
Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Colonic Neoplasms; DNA, Antisense; DNA, Complementary; Drug Synergism; Flavonoids; GTP-Binding Proteins; Humans; Irinotecan; Male; Mice; Mice, Nude; Piperidines; Prodrugs; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs.
Topics: Alleles; Amino Acid Sequence; Antineoplastic Agents; Binding, Competitive; Black People; Blotting, Western; Camptothecin; Flavonoids; Glucuronates; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Kinetics; Molecular Sequence Data; Mutation, Missense; Piperidines; Polymorphism, Genetic; Recombinant Proteins; Sequence Homology, Amino Acid; Subcellular Fractions; UDP-Glucuronosyltransferase 1A9; White People | 2003 |
A case of small cell carcinoma of the kidney.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Humans; Irinotecan; Kidney Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Piperidines | 2007 |
Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Drug Administration Schedule; ErbB Receptors; Female; Humans; Irinotecan; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome | 2007 |
The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Colonic Neoplasms; Cyclin-Dependent Kinase 9; Down-Regulation; Drug Synergism; Flavonoids; HCT116 Cells; Humans; Irinotecan; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Rad51 Recombinase; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Topoisomerase I Inhibitors; Tumor Suppressor Protein p53 | 2008 |
Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Cell Line; Cell Line, Tumor; Dogs; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gefitinib; Humans; Irinotecan; Mitoxantrone; Neoplasm Proteins; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Time Factors | 2010 |
Combination of vandetanib, radiotherapy, and irinotecan in the LoVo human colorectal cancer xenograft model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Dose Fractionation, Radiation; ErbB Receptors; Humans; Irinotecan; Mice; Mice, Nude; Piperidines; Protein Kinase Inhibitors; Quinazolines; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents.
Topics: Algorithms; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Proliferation; Drug Evaluation, Preclinical; Drug Synergism; Flavonoids; Genes, cdc; Growth Inhibitors; Humans; Irinotecan; Mice; Mice, Nude; Models, Statistical; Neoplasm Transplantation; Piperidines; Predictive Value of Tests; Thiophenes; Urea; Xenograft Model Antitumor Assays | 2010 |
Discovery of drug mode of action and drug repositioning from transcriptional responses.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Algorithms; Antineoplastic Agents; Autophagy; Blotting, Western; Camptothecin; Cell Line, Tumor; Doxorubicin; Drug Discovery; Drug Screening Assays, Antitumor; Flavonoids; Fuzzy Logic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Irinotecan; Neoplasms; Oligonucleotide Array Sequence Analysis; Phosphorylation; Piperidines; Pyrazoles; Pyrroles; RNA Polymerase II | 2010 |
A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Piperidines; Quinazolines; Retrospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Preclinical study of treatment response in HCT-116 cells and xenografts with (1) H-decoupled (31) P MRS.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Cycle; Choline Kinase; Choline-Phosphate Cytidylyltransferase; Colorectal Neoplasms; Female; Flavonoids; HCT116 Cells; Humans; Irinotecan; Magnetic Resonance Spectroscopy; Mice; Phosphorus Isotopes; Piperidines; Protons; Saccharomyces cerevisiae; Treatment Outcome; Xenograft Model Antitumor Assays | 2011 |
BBA, a derivative of 23-hydroxybetulinic acid, potently reverses ABCB1-mediated drug resistance in vitro and in vivo.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Breast Neoplasms; Calcium Channel Blockers; Camptothecin; Carcinoma, Hepatocellular; Cell Proliferation; Cells, Cultured; Cisplatin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorescent Antibody Technique; Humans; In Vitro Techniques; Irinotecan; KB Cells; Liver Neoplasms; Male; Mice; Mice, Nude; Models, Molecular; Molecular Docking Simulation; Paclitaxel; Piperidines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Triterpenes; Verapamil | 2012 |
Nanoencapsulation of Novel Inhibitors of PNKP for Selective Sensitization to Ionizing Radiation and Irinotecan and Induction of Synthetic Lethality.
Topics: Chemoradiotherapy; Colorectal Neoplasms; DNA Repair; DNA Repair Enzymes; Drug Compounding; Drug Resistance, Neoplasm; HCT116 Cells; Humans; Irinotecan; Micelles; Nanocapsules; Phosphotransferases (Alcohol Group Acceptor); Piperidines; Radiation, Ionizing; Synthetic Lethal Mutations | 2018 |
Predicting pharmacokinetic behaviour of drug release from drug-eluting embolization beads using in vitro elution methods.
Topics: Animals; Chemoembolization, Therapeutic; Doxorubicin; Drug Delivery Systems; Drug Liberation; In Vitro Techniques; Irinotecan; Liver; Liver Neoplasms; Piperidines; Quinazolines; Swine | 2019 |
Irinotecan and vandetanib create synergies for treatment of pancreatic cancer patients with concomitant TP53 and KRAS mutations.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Synergism; Female; Humans; Irinotecan; Male; Mutation; Pancreatic Neoplasms; Piperidines; Proto-Oncogene Proteins p21(ras); Quinazolines; Survival Rate; Tumor Suppressor Protein p53 | 2021 |
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colorectal Neoplasms; Female; Humans; Indazoles; Irinotecan; Mice; Mice, Nude; Mutation; Piperidines | 2021 |